Skip to Content

MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine) Disease Interactions

There are 3 disease interactions with MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine):

Major

Vaccines (Includes MenHibrix) ↔ Im Injection

Severe Potential Hazard, Moderate plausibility

Applies to: Thrombocytopenia, Thrombocytopathy, Coagulation Defect, Thrombocytopenia, Thrombocytopathy, Coagulation Defect

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
  3. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 5 references
Moderate

Meningococcal Conjugate Vaccine (Includes MenHibrix) ↔ Gbs

Moderate Potential Hazard, Moderate plausibility

Applies to: Guillain-Barre Syndrome

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.

Moderate

Vaccines (Live Attenuated/Toxoid) (Includes MenHibrix) ↔ Immunocompromised

Moderate Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency, Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine) drug Interactions

There are 195 drug interactions with MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine)

More about MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine)

Related treatment guides

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide